Clinical Trial Update: Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion [Phase 3]

View source ↗

Summary

Phase 3 trial comparing brolucizumab to aflibercept in macular edema due to central retinal vein occlusion was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Retinal Vein Occlusion

Drugs mentioned

• Aflibercept (Aflibercept)
• Brolucizumab (brolucizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Central Retinal Vein Occlusion | Phase 3 | Status: TERMINATED | Results posted: 2022-08-08